Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jordan Perlman"'
Autor:
Kacey Chae, MD, Jordan Perlman, MD, Ryan B. Fransman, MD, Christopher L. Wolfgang, MD, PhD, Ana De Jesus-Acosta, MD, Nestoras Mathioudakis, MD
Publikováno v:
AACE Clinical Case Reports, Vol 7, Iss 6, Pp 379-382 (2021)
Objective: We describe a rare case of profound subcutaneous insulin resistance (SIR) presumed due to a paraneoplastic process caused by pancreatic adenocarcinoma that improved with intravenous insulin and tumor resection. Methods: An 80-year-old man
Externí odkaz:
https://doaj.org/article/6f8d0a8eb44945a6a5ece0113c149824
Autor:
Kramer, Shira
Publikováno v:
Baltimore Jewish Times; 1/5/2024, Vol. 395 Issue 1, p9-9, 1p
Autor:
Ana De Jesus-Acosta, Kacey Chae, Nestoras Mathioudakis, Ryan B. Fransman, Jordan Perlman, Christopher L. Wolfgang
Publikováno v:
AACE Clinical Case Reports
AACE Clinical Case Reports, Vol 7, Iss 6, Pp 379-382 (2021)
AACE Clinical Case Reports, Vol 7, Iss 6, Pp 379-382 (2021)
Objective We describe a rare case of profound subcutaneous insulin resistance (SIR) presumed due to a paraneoplastic process caused by pancreatic adenocarcinoma that improved with intravenous insulin and tumor resection. Methods An 80-year-old man wi
Autor:
Jordan Perlman, Jennifer Mammen
Publikováno v:
Journal of the Endocrine Society. 6:A443-A444
Checkpoint inhibitor-induced diabetes mellitus (CIADM) is a rare but morbid complication of cancer immunotherapies. The most common presentation is acute hyperglycemia and severe insulin deficiency. Our experience managing 25 patients in our new Immu
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67189 (2013)
Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR
Externí odkaz:
https://doaj.org/article/470e357e8eee443d894e89877c3017e0
Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67189 (2013)
PLoS ONE
PLoS ONE
Aims/Hypothesis Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of ra
Publikováno v:
Journal of the Endocrine Society; 2023 Supplement, Vol. 7, pA1-A1170, 3258p
Publikováno v:
Journal of the Endocrine Society; 2022 Supplement, Vol. 6, pA430-A450, 60p
Publikováno v:
Journal of the Endocrine Society; Apr2023, Vol. 7 Issue 4, p1-3, 3p
Publikováno v:
Diabetes Technology & Therapeutics; Jan2022, Vol. 24 Issue 1, p79-80, 2p